Opaleye Management Inc. Has $12.02 Million Holdings in Cabaletta Bio, Inc. $CABA

Posted by Brian Himes on Sep 11th, 2026

Opaleye Management Inc. increased its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 180.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,863,800 shares of the company’s stock after purchasing an additional 2,483,800 shares during the period. Cabaletta Bio comprises about 1.1% of Opaleye Management Inc.’s investment portfolio, making the stock its 26th largest position. Opaleye Management Inc.’s holdings in Cabaletta Bio were worth $12,016,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Kestra Advisory Services LLC bought a new stake in Cabaletta Bio in the 1st quarter valued at $32,000. SummitTX Capital L.P. acquired a new stake in shares of Cabaletta Bio during the 1st quarter valued at about $34,000. Legal & General Group Plc bought a new stake in Cabaletta Bio in the second quarter valued at about $34,000. HighTower Advisors LLC bought a new stake in Cabaletta Bio in the second quarter valued at about $34,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in Cabaletta Bio in the fourth quarter worth about $38,000.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CABA shares. Wells Fargo & Company decreased their price objective on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. Wall Street Zen cut Cabaletta Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Jefferies Financial Group restated a “buy” rating on shares of Cabaletta Bio in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Friday, July 17th. Finally, TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a research report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cabaletta Bio currently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Check Out Our Latest Stock Report on Cabaletta Bio

Cabaletta Bio Stock Performance

Shares of CABA opened at $2.74 on Friday. The stock has a fifty day moving average price of $2.95 and a two-hundred day moving average price of $3.12. Cabaletta Bio, Inc. has a 52-week low of $1.72 and a 52-week high of $4.23. The company has a market cap of $464.54 million, a price-to-earnings ratio of -1.75 and a beta of 3.27.

Cabaletta Bio (NASDAQ:CABA – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. As a group, research analysts predict that Cabaletta Bio, Inc. will post -1.34 EPS for the current fiscal year.

Cabaletta Bio Company Profile

(Free Report)

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.